JDB153 plus Penpulimab for advanced liver cancer after prior therapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of two drugs—JDB153 and Penpulimab—for people with advanced hepatocellular carcinoma (liver cancer) that has stopped responding to or gotten worse on standard treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (hepatocellular carcinoma) that cannot be surgically removed or has spread to other parts of your body.
- You are between 18 and 75 years old.
- Your cancer got worse after receiving at least one prior standard treatment (like targeted therapy or immunotherapy).
- You have at least one measurable tumor that can be seen on a CT or MRI scan.
- Your liver function is good enough (Child-Pugh score of 7 or less).
- You do not have active hepatitis B or C, HIV, or a serious autoimmune disease requiring strong immune-suppressing medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
This trial tests if adding rituximab to previous cancer treatments can help people with advanced hepatocellular carcinoma (a type of liver cancer) that has stopped responding or caused side effects. It aims to see if this combination is safe and effective.
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
This trial tests if removing the main liver tumor with surgery, followed by targeted therapy and immunotherapy, can help people with advanced liver cancer that has spread a little. It is for those who have not had prior treatment and whose liver is still working well.
This trial tests a new combination therapy using special immune cells (gamma-delta T cells) along with targeted drugs and immunotherapy for people with advanced liver cancer that is no longer responding to standard treatment. The goal is to see if this approach can help shrink tumors or slow their growth.
Hear when a new Refractory Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.